JY231
Phase 1Biologic
JY231 is one of 166 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.
5
Indications
12
Total Trials
12
Active Trials
165
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Oncaspar
SServier
Preclinical
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
JY231
SShenzhen Genocury Biotech Co., Ltd.
Phase 1
Tafasitamab
IncytePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
CAR-T
HHebei Senlang Biotechnology Inc., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Leukemia5 trials
Show 2 more trials
Autoimmune Disease2 trials
B-cell Malignancies1 trial
JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies
Recruiting·—·N/A·NCT07065279·36 enrolled
2 more indications
Systemic Lupus Erythematosus1 trial
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
Recruiting·—·Phase 1/2·NCT06675422·20 enrolled
B-cell acute lymphoblastic leukemia1 trial
JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
Recruiting·—·Phase 1·NCT06514768·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JY231. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details